The Oncology Institute, Inc. (STLN) - Net Assets
Based on the latest financial reports, The Oncology Institute, Inc. (STLN) has net assets worth $-24.91 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($178.23 Million) and total liabilities ($203.15 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore The Oncology Institute, Inc. (STLN) equity growth momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-24.91 Million |
| % of Total Assets | -13.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 219.48 |
The Oncology Institute, Inc. - Net Assets Trend (2022–2025)
This chart illustrates how The Oncology Institute, Inc.'s net assets have evolved over time, based on quarterly financial data. Check strategic asset allocation of The Oncology Institute, Inc. to assess the company's strategic physical and investment asset allocation.
Annual Net Assets for The Oncology Institute, Inc. (2022–2025)
The table below shows the annual net assets of The Oncology Institute, Inc. from 2022 to 2025. For live market cap and overall valuation, see STLN market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-15.72 Million | -538.01% |
| 2024-12-31 | $3.59 Million | -93.71% |
| 2023-12-31 | $57.02 Million | -53.70% |
| 2022-12-31 | $123.17 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to The Oncology Institute, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 20833700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $255.70 Million | % |
| Total Equity | $-15.72 Million | 100.00% |
The Oncology Institute, Inc. Competitors by Market Cap
The table below lists competitors of The Oncology Institute, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Properties & Resources Development Group Ltd
SHE:000011
|
$640.96 Million |
|
Innova Captab Limited
NSE:INNOVACAP
|
$641.15 Million |
|
Skipper Limited
NSE:SKIPPER
|
$641.46 Million |
|
Guangdong Super Telecom
SHG:603322
|
$641.53 Million |
|
Bestlink Tech Co Ltd
SHG:603206
|
$640.88 Million |
|
Forward Air Corporation
NASDAQ:FWRD
|
$640.49 Million |
|
CoinShares PLC Ordinary Shares
NASDAQ:CSHR
|
$640.45 Million |
|
ESGL Holdings Limited
NASDAQ:OIO
|
$640.36 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in The Oncology Institute, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,589,000 to -15,720,000, a change of -19,309,000 (-538.0%).
- Net loss of 60,606,000 reduced equity.
- New share issuances of 29,200,000 increased equity.
- Other factors increased equity by 12,097,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-60.61 Million | -385.53% |
| Share Issuances | $29.20 Million | +185.75% |
| Other Changes | $12.10 Million | +76.95% |
| Total Change | $- | -538.01% |
Book Value vs Market Value Analysis
This analysis compares The Oncology Institute, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $1.68 | $6.45 | x |
| 2023-12-31 | $0.77 | $6.45 | x |
| 2024-12-31 | $0.05 | $6.45 | x |
| 2025-12-31 | $-0.16 | $6.45 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently The Oncology Institute, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.06%
- • Asset Turnover: 3.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-486.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.12% | 0.06% | 0.96x | 2.12x | $-12.17 Million |
| 2023 | -145.67% | -25.62% | 1.55x | 3.67x | $-88.77 Million |
| 2024 | -1801.70% | -16.44% | 2.28x | 48.12x | $-65.02 Million |
| 2025 | 0.00% | -12.06% | 3.05x | 0.00x | $-59.03 Million |
Industry Comparison
This section compares The Oncology Institute, Inc.'s net assets metrics with peer companies in the Medical Care Facilities industry.
Industry Context
- Industry: Medical Care Facilities
- Average net assets among peers: $249,138,442
- Average return on equity (ROE) among peers: 9047.08%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| The Oncology Institute, Inc. (STLN) | $-24.91 Million | 0.12% | N/A | $640.89 Million |
| Acadia Healthcare Company Inc (ACHC) | $96.36 Million | -36.21% | 3.29x | $1.52 Billion |
| Addus HomeCare Corporation (ADUS) | $158.93 Million | 7.57% | 0.45x | $1.69 Billion |
| agilon health Inc (AGL) | $126.73 Million | -319.84% | 9.03x | $1.60 Billion |
| Airsculpt Technologies Inc (AIRS) | $120.39 Million | -1.84% | 0.42x | $231.79 Million |
| Amedisys Inc (AMED) | $454.23 Million | -18.40% | 0.61x | $3.32 Billion |
| AMN Healthcare Services Inc (AMN) | $831.26 Million | 25.34% | 2.52x | $624.22 Million |
| American Shared Hospital Service (AMS) | $-8.37 Million | 0.00% | 0.00x | $8.87 Million |
| American Oncology Network Inc. (AONC) | $24.17K | 90834.23% | 1.03x | $336.36 Million |
| Ardent Health Partners, Inc. (ARDT) | $711.84 Million | -20.09% | 2.86x | $1.56 Billion |
| Astrana Health Inc (ASTH) | $-17.74K | 0.00% | 0.00x | $1.77 Billion |
About The Oncology Institute, Inc.
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educatio… Read more